SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

News > Research

Read more breaking news

 

 
Celiac Disease breakthrough?

Natural protein elafin ‘promising’ in battle against gluten toxicity: Study

By Kacey Culliney+

08-Apr-2014
Last updated on 11-Apr-2014 at 12:49 GMT2014-04-11T12:49:18Z

The natural protein elafin is less abundant in people with celiac disease which could explain gut inflammation association with the disorder, the scientists say
The natural protein elafin is less abundant in people with celiac disease which could explain gut inflammation association with the disorder, the scientists say

The human protein elafin could be delivered into the gut using a probiotic bacterium to reduce the inflammatory reaction typical of celiac disease, researchers suggest.

The patent-pending strategy has been developed by teams at the French National Institute for Agricultural Research (INRA) and the French National Institute of Health and Medical Research (INSERM) along with Canadian and Swiss colleagues.

Published online in the American Journal of Gastroenterology today (April 8), scientists delivered the elafin molecule using a food-grade strain of L. lactis successfully in mice for the first time.

INRA said findings opened up “promising prospects to treat celiac disease and gluten intolerance in general”.

The researchers said: “This molecule may have pathophysiological and therapeutic importance in gluten-related disorders.”

Elafin and its role in the gut

In the same study, in vitro testing found that elafin, a protease inhibitor, played a key role in fighting against inflammatory reactions in the gut that were typical of celiac disease, ultimately reducing gluten toxicity.

The protein prevented the destruction of the gut barrier during inflammation and interacted with enzymes responsible for the abnormal breakdown of gluten: transglutaminase-2, the researchers said.

“Our in vitro results point at an exciting novel role and specific mechanism of action of elafin in celiac disease that should be further explored.”

However, they found that the protein was less abundant in patients with celiac disease compared to healthy people; a loss that could be contributing to enhanced inflammation in celiac disease.

Delivery with a lactic bacterium strain

The lack of natural elafin molecules in those with celiac disease prompted the researchers to investigate methods of delivery. The scientists successfully delivered the protein to mice using a lactic bacterium strain Lactococcus lactis.

Findings showed that elafin delivery at the mucosal level prevented gluten-induced barrier dysfunction and inflammation.

“The use of this strain, developed by the same teams from INRA and INSERM, enables a targeted and local production of elafin, and represents a recent and innovative strategy,” INRA said.

The researchers said replacement of elafin molecules in celiac patients could have potential as adjuvant therapy in gluten-related disorders but said it was important to investigate details further.

The next step, they said, would be to define the mechanisms underlying the positive effects of elafin in celiac disease and identifying bacteria that naturally produce proteins with anti-inflammatory properties similar to elafin.

 

Source: American Journal of Gastroenterology
Published online ahead of print, April 8 2014. Doi: 10.1038/ajg.2014.48
“Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders”
Authors: HJ. Galipeau et al.

*If you are interested in celiac disease and gluten-free food development, FoodNavigator-USA is hosting an online forum 'Gluten-free in perspective' on April 30. Click HERE to register for free.

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars